A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma

[1]  Z. Ding,et al.  PD-1 Inhibitors in the Advanced Esophageal Cancer , 2019, Front. Pharmacol..

[2]  P. Hoff,et al.  Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil , 2019, Journal of global oncology.

[3]  A. Bode,et al.  Targeted therapy of the AKT kinase inhibits esophageal squamous cell carcinoma growth in vitro and in vivo , 2019, International journal of cancer.

[4]  T. Hori,et al.  Prognostic factors in patients who received end-of-life chemotherapy for advanced cancer , 2018, International Journal of Clinical Oncology.

[5]  Kazuhiro Yoshida,et al.  Recent advancements in esophageal cancer treatment in Japan , 2018, Annals of gastroenterological surgery.

[6]  H. Katayama,et al.  Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303) , 2017, International Journal of Clinical Oncology.

[7]  Y. Tachimori,et al.  Comprehensive Registry of Esophageal Cancer in Japan, 2009 , 2016, Esophagus.

[8]  K. Hirakawa,et al.  Glasgow Prognostic Score as a Prognostic Clinical Marker in T4 Esophageal Squamous Cell Carcinoma. , 2015, Anticancer research.

[9]  Ken Kato,et al.  A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy , 2014, Cancer Chemotherapy and Pharmacology.

[10]  Y. Doki,et al.  Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) , 2014, Cancer science.

[11]  K. Hirakawa,et al.  Low Nutritional Prognostic Index Correlates with Poor Survival in Patients with Stage IV Colorectal Cancer Following Palliative Resection of the Primary Tumor , 2014, World Journal of Surgery.

[12]  K. Muro,et al.  A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) , 2014, Esophagus.

[13]  T. Tsujinaka,et al.  Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). , 2012, Anticancer research.

[14]  Yasuo Hamamoto,et al.  A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy , 2011, Cancer Chemotherapy and Pharmacology.

[15]  T. Aoki,et al.  Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer. , 2011, Anticancer research.

[16]  M. Kanda,et al.  Nutritional predictors of postoperative outcome in pancreatic cancer , 2011, The British journal of surgery.

[17]  T. Nozoe,et al.  Prognostic nutritional Index: A tool to predict the biological aggressiveness of gastric carcinoma , 2010, Surgery Today.

[18]  I. Hyodo,et al.  A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  D C McMillan,et al.  Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer , 2003, British Journal of Cancer.

[20]  H. Yamana,et al.  Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). , 2001, Japanese journal of clinical oncology.

[21]  L. Collette,et al.  Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. , 1997, European journal of cancer.

[22]  A. van der Gaast,et al.  Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. , 1996, British Journal of Cancer.

[23]  H. Watanabe,et al.  Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. , 1992, Japanese journal of clinical oncology.

[24]  H. Watanabe,et al.  Phase II evaluation of combined cisplatin and vindesine in advanced squamous cell carcinoma of the esophagus: Japanese Esophageal Oncology Group Trial. , 1991, Japanese journal of clinical oncology.

[25]  E. Alba,et al.  Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer. , 1988, European journal of cancer & clinical oncology.

[26]  G. Lyman,et al.  Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial. , 1986, Cancer treatment reports.

[27]  M. Bains,et al.  Cisplatin and bleomycin in the treatment of esophageal carcinoma: A final report , 1984, Cancer.

[28]  M. Shinoda,et al.  A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) , 2011, Annals of Surgical Oncology.

[29]  Japanese Society of Esophageal Diseases.  Comprehensive registry of esophageal cancer in Japan, 1999 , 2005, Esophagus.